VT News
Marco van den Berg

Marco van den Berg

Ask VT AI
View News Summary
  • Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.
  • Elon Musk's xAI faces executive turmoil as key leaders depart amid rapid growth and expansion.
  • Washington DC sues Trump over National Guard deployment, arguing it violates city's autonomy and constitutes illegal military occupation.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.
  • Elon Musk's xAI faces executive turmoil as key leaders depart amid rapid growth and expansion.
  • Washington DC sues Trump over National Guard deployment, arguing it violates city's autonomy and constitutes illegal military occupation.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Marco van den Berg

Top Topics

Trending in U.S.

World

Sport